Home・Aktien・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

280.45 0.11

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

278.27

Max

286.83

Schlüsselkennzahlen
By Trading Economics
Einkommen	62M 49M
Verkäufe	12M 64M
KGV Branchendurchschnitt	29.524 57.366
EPS	2.22
Gewinnspanne	76.159
Angestellte	47
EBITDA	87M 72M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+25.23% upside

Dividenden
By Acuity
Nächstes Ergebnis	5. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-267M 5.6B
Vorheriger Eröffnungskurs	280.34
Vorheriger Schlusskurs	280.45

Nachrichtenstimmung

By Acuity

35%

65%

136 / 340 Ranking in Healthcare

Ligand Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Aug. 2026, 19:46 UTC

Ligand Pharmaceuticals Inc is trading higher, benefiting from a favorable market environment amid declining crude oil prices and lower Treasury yields.

24. Aug. 2026, 19:56 UTC

Ligand Pharmaceuticals is trading lower during Monday's session, marking the fourth consecutive day of declines. No specific news has been identified to explain the drop.

21. Aug. 2026, 19:36 UTC

News

Ligand Pharmaceuticals is gaining today, supported by strong long-term performance and a market capitalization of $5.76 billion.

19. Aug. 2026, 19:11 UTC

Ligand Pharmaceuticals Inc is rising today, driven by strong momentum in the Pharmaceuticals sub-sector and unusually high market volume.

18. Aug. 2026, 19:16 UTC

Ligand Pharmaceuticals Inc is trading lower, continuing a downward trend amid rising U.S. Treasury yields and inflation concerns related to geopolitical tensions.

17. Aug. 2026, 20:06 UTC

Ligand Pharmaceuticals Inc is declining during Monday's session, amid broader economic concerns following a drop in U.S. retail sales for July.

14. Aug. 2026, 19:46 UTC

News

Ligand Pharmaceuticals Inc shares are higher after Leerink analyst David Risinger initiated coverage with an Outperform rating and a price target of $330.00.

13. Aug. 2026, 19:52 UTC

News

Ligand Pharmaceuticals Inc shares are lower amid high trading volume, as initial jobless claims rose and the Producer Price Index remained flat.

12. Aug. 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are higher today, reflecting strength in U.S. stocks amid gains in AI-related companies and ongoing geopolitical tensions.

11. Aug. 2026, 19:16 UTC

Ligand Pharmaceuticals Inc shares are lower today, experiencing volatility amid rising oil prices and inflation concerns ahead of key U.S. inflation data.

10. Aug. 2026, 21:51 UTC

Ligand Pharmaceuticals Inc shares declined in after-market hours, continuing a downward trend with no specific news to explain the movement.

7. Aug. 2026, 20:02 UTC

News

Ligand Pharmaceuticals Inc shares are lower despite a strong second-quarter performance, as profit-taking and high trading volume weigh on the stock.

6. Aug. 2026, 20:03 UTC

News

Ligand Pharmaceuticals Inc reported strong Q2 results, with adjusted EPS of $2.37, exceeding expectations. The company raised its full-year EPS guidance amid sector gains.

5. Aug. 2026, 19:26 UTC

Ligand Pharmaceuticals Inc shares are higher during Wednesday's session, despite pulling back from earlier gains. Broader market sentiment is supported by declining crude oil prices.

3. Aug. 2026, 19:36 UTC

News

Oppenheimer raised its price target on Ligand Pharmaceuticals to $326, reinforcing positive investor sentiment as shares trade higher during Monday's session.

31. Juli 2026, 23:36 UTC

Ligand Pharmaceuticals Inc shares are lower in after-market trading, influenced by broader market pressure from Apple's weaker guidance. No specific company news was identified.

30. Juli 2026, 22:16 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market hours, despite routine trading and no specific news driving the price action.

29. Juli 2026, 21:02 UTC

Ligand Pharmaceuticals Inc. shares are higher in after-market hours, despite broader market volatility and a six-session decline leading up to today.

28. Juli 2026, 19:22 UTC

Ligand Pharmaceuticals Inc is lower today, continuing a five-session decline, with no specific news driving the movement and unusually high trading volume.

27. Juli 2026, 19:26 UTC

News

Ligand Pharmaceuticals Inc. shares are lower today, continuing a four-session decline amid concerns over its recent acquisition of XOMA Royalty Corp.

24. Juli 2026, 22:06 UTC

Ligand Pharmaceuticals Inc. shares were little changed in after-market trading, with no specific news identified. Broader market trends showed mixed signals.

23. Juli 2026, 21:03 UTC

Ligand Pharmaceuticals Inc shares are higher in after-market trading, following a rise in crude oil prices amid geopolitical tensions, though no specific company news was identified.

21. Juli 2026, 20:02 UTC

News

Ligand Pharmaceuticals is higher after Citi resumed coverage with a Buy rating and a price target of $387, citing benefits from the XOMA acquisition.

Peer-Vergleich

Kursveränderung

Ligand Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

25.23% Vorteil

12-Monats-Prognose

Durchschnitt 350.86 USD 25.23%

Hoch 390 USD

Tief 326 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ligand Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Ligand Pharmaceuticals Inc – Dist abgegeben haben.

Stimmung

By Acuity

136 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.